AHA 2021: New research showed MK-0616, an investigative oral PCSK9 inhibitor, was associated with a near 65% decrease in LDL-C.
AHA 2021: Study suggests remote hypertension and hyperlipidemia management programs may expand telehealth delivery, increase access to care, and reduce health inequities.
EASD 2021: For persons who have had obesity, returning to a healthy weight may reduce risk for hypertension and dyslipidemia, and modestly for diabetes.
EASD 2021: Women with type 2 diabetes were less likely to meet targets for CV risk management vs men but at lower risk for future CV events, a new study found.
Clinical decisions on LDL-C management currently rely on a measure at one time point, typically middle age. A new study suggests burden begins early and so should assessment.
Nathan D Wong, PhD, MPH, renowned in the field of preventive cardiology, reviewed for Patient Care the history of the field and his own pivotal contributions and also paid tribute to his lifetime mentors.
Assessment of CVD risk is the foundation of primary prevention and integral to primary care. Brush up on the fundamental tools of risk estimation from the ACC/AHA guidelines.
The FDA requests removal of pregnancy contraindication from statin prescribing information based on comprehensive reviews that found no evidence of an increase in birth defects.
In patients with stable vascular disease from the COMPASS trial, the combination of rivaroxaban and aspirin effectively reduced ischemic events despite multiple comorbidities and polypharmacy.
A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.